Read more
Informationen zum Autor Dr Michael R. Hamblin is a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital and an Associate Professor of Dermatology at Harvard Medical School. He received his PhD in synthetic organic chemistry from Trent University in England. His interests lie in photodynamic therapy for infections, cancer, and heart disease and also in low-level light therapy for wound healing, arthritis, traumatic brain injury and hair regrowth. His research program is supported by NIH, CDMRP and CIMIT among others. He has published over 125 peer-reviewed articles, over 120 conference proceedings, book chapters and international abstracts, and holds 8 patents. Klappentext This book is the first to comprehensively cover this interesting and rapidly spreading topic, namely the use of visible light and photosensitising agents for controlling the population of microbial pathogens. Edited by two pioneers in the application of this technique for addressing both medical and environmental issues, and bringing together the foremost practitioners internationally in this field, this up-to-date account will address basic/mechanistic aspects followed by an exhaustive coverage of the current medical applications and environmentally friendly approaches. The book will be an indispensable resource for students and professionals working in fields relating to photochemistry, environmental science and medical applications for photodynamic therapy. Zusammenfassung The first book to comprehensively cover the use of light and photosensitising agents for controlling the population of microbial pathogens. Inhaltsverzeichnis Antimicrobial Photodynamic Therapy: Basic Principles; Phenothiazinium Salts as Antimicrobial Photosensitising Agents; Approaches to Kill Gram-negative Bacteria by Photosensitized Processes; Innovative design of antimicrobial photosensitizers; Porphyrins as antimicrobial photosensitizing agents; Fullerene Derivatives as Antimicrobial Photosensitising Agents; Photosensitiser Delivery for Photodynamic Antimicrobial Chemotherapy; Photodynamic therapy of localized infections in animal models; Pathogen Reduction In Blood For Transfusion Using Photodynamic Treatments; PDT for Acne; PDT for Viral Lesions; PDT For Cutaneous Leishmaniasis; Antimicrobial Photodynamic Therapy (aPDT) for oral infections; Photodynamic antifungal chemotherapy; Photodynamic Therapy for Wound Infections; Photodynamic Therapy for Helicobacter pylori Infections; Inactivation Of Microbial Pathogens By Photosensitised Processes: Environmental Applications; Subject Index...
List of contents
Antimicrobial Photodynamic Therapy: Basic Principles; Phenothiazinium Salts as Antimicrobial Photosensitising Agents; Approaches to Kill Gram-negative Bacteria by Photosensitized Processes; Innovative design of antimicrobial photosensitizers; Porphyrins as antimicrobial photosensitizing agents; Fullerene Derivatives as Antimicrobial Photosensitising Agents; Photosensitiser Delivery for Photodynamic Antimicrobial Chemotherapy; Photodynamic therapy of localized infections in animal models; Pathogen Reduction In Blood For Transfusion Using Photodynamic Treatments; PDT for Acne; PDT for Viral Lesions; PDT For Cutaneous Leishmaniasis; Antimicrobial Photodynamic Therapy (aPDT) for oral infections; Photodynamic antifungal chemotherapy; Photodynamic Therapy for Wound Infections; Photodynamic Therapy for Helicobacter pylori Infections; Inactivation Of Microbial Pathogens By Photosensitised Processes: Environmental Applications; Subject Index
About the author
Dr Michael R. Hamblin is a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital and an Associate Professor of Dermatology at Harvard Medical School. He received his PhD in synthetic organic chemistry from Trent University in England. His interests lie in photodynamic therapy for infections, cancer, and heart disease and also in low-level light therapy for wound healing, arthritis, traumatic brain injury and hair regrowth. His research program is supported by NIH, CDMRP and CIMIT among others. He has published over 125 peer-reviewed articles, over 120 conference proceedings, book chapters and international abstracts, and holds 8 patents.
